These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3690547)

  • 1. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.
    Oishi N; Berenberg J; Blumenstein BA; Johnson K; Rivkin SE; Bukowski RM; O'Bryan RM; Stephens RL; Quagliana J; Saiers JH
    Cancer Treat Rep; 1987 Dec; 71(12):1307-8. PubMed ID: 3690547
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
    Rodriguez LH; Johnson DE; Holoye PY; Samuels ML
    Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract].
    Aso Y; Ushiyama T; Suzuki K; Tajima A; Naide Y; Ohshima S; Matsuura O; Fukushima M; Ota K; Ono Y
    Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1046-51. PubMed ID: 3418215
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma].
    Nakagami Y; Lin TT; Ito H; Hirasawa S; Tannawa K; Fujioka Y; Ogawa H; Tanaka K; Yamada N; Ishii Y
    Hinyokika Kiyo; 1987 Oct; 33(10):1728-32. PubMed ID: 3128071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of VM-26 as a single agent in the treatment of renal carcinoma.
    Hire EA; Samson MK; Fraile RJ; Baker LH
    Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
    Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT
    Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of etoposide for pulmonary metastases from urogenital tract cancer].
    Fujita K; Murayama T; Sayama T
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2438-41. PubMed ID: 6497402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 11. VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors.
    Mechl Z; Rovný F; Sopková B
    Neoplasma; 1977; 24(4):411-4. PubMed ID: 904743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open clinical uro-oncology trials in Canada.
    Rodrigues G; Winquist E; Mackenzie MJ
    Can J Urol; 2009 Aug; 16(4):4795-800. PubMed ID: 19671240
    [No Abstract]   [Full Text] [Related]  

  • 13. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
    Muss H; Bundy BN; DiSaia PJ; Twiggs LB
    Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of amsacrine (AMSA) in previously treated patients with advanced transitional cell carcinoma of the urothelium: a National Bladder Cancer Collaborative Group A study.
    Trump DL; Loening S; Ahmed SW; Wajsman Z
    Cancer Treat Rep; 1983 Sep; 67(9):845-6. PubMed ID: 6688377
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
    Locker GY; Lanzotti V; Khandekar JD; Sweet D; Shaw J; Bitran J; Gordon L; Krauss S; Johnson C
    Cancer Treat Rep; 1986 Feb; 70(2):307-8. PubMed ID: 3948195
    [No Abstract]   [Full Text] [Related]  

  • 16. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.
    Schulman CC; Robinson M; Denis L; Smith P; Viggiano G; de Pauw M; Dalesio O; Sylvester R
    Eur Urol; 1982; 8(4):207-12. PubMed ID: 6807679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chemotherapy in the management of metastatic bladder cancer.
    Garcia-Giralt E; Auvert J; Lachand AT; Botto H; Abbou C; Hannoun M; Pouillart P; Palangie T; Jouve M; Morin P
    Br J Urol; 1981 Aug; 53(4):318-9. PubMed ID: 7260545
    [No Abstract]   [Full Text] [Related]  

  • 18. Teniposide in squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Yazigi R; Yordan E
    Cancer Treat Rep; 1987 Sep; 71(9):873-4. PubMed ID: 3621222
    [No Abstract]   [Full Text] [Related]  

  • 19. [Guideline for proper use of antineoplastic agents. Urologic cancer].
    Akaza H; Miyanaga N
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):1055-64. PubMed ID: 12109446
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of teniposide in small cell carcinoma of the lung.
    Pedersen AG; Bork E; Osterlind K; Dombernowsky P; Hansen HH
    Cancer Treat Rep; 1984 Oct; 68(10):1289-91. PubMed ID: 6098366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.